Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Tigermed Pays $50 Million to Acquire Frontage Labs, a US/China CRO

publication date: May 7, 2014
Hangzhou Tigermed Consulting, a China clinical-stage CRO, will add pre-clinical capability to its service offerings by acquiring a 70% stake in Frontage Labs, headquartered in Pennsylvania, for $50.2 million. Frontage Labs provides both pre-clinical and clinical CRO services through its facilities in Pennsylvania and the Zhangjiang Hi-Tech Park in Shanghai. Tigermed said Frontage would continue to operate independently, with its current management team, led by CEO Dr. Song Li, remaining intact. More details....

Stock Symbol: (SHE: 300347)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital